Peers Perspectives

Experts discuss the importance of early screening for type 1 diabetes, screening guidelines, and emerging treatments that can delay the onset of type 1 diabetes.

An expert physician assistant and a nurse practitioner discuss the role of long-term and real-world data regarding the safety and efficacy of IL-23 inhibitors in the management of patients with plaque psoriasis.

Expert healthcare practitioners discuss insulin delivery methods, focusing on inhaled insulin, its pharmacological properties, and data on glycemic control in type 1 diabetes. The panelists also talk about the use of inhaled insulin in type 2 diabetes and emerging data on oral insulin.

Advanced practice practitioners discuss the co-occurrence of sleep disorders with other health conditions, patient awareness, and the importance of screening for sleep disorders. They also discuss the treatment landscape of insomnia and the use of dual orexin receptor antagonists in the management of insomnia.

Expert dermatologist and physician assistant review updates in the management of Plaque Psoriasis.

Expert perspectives on the management of psoriatic arthritis with a focus on ensuring treatment adherence and compliance as part of optimal care.

Updated recommendations to managing type 2 diabetes with SGLT2 inhibitors and GLP-1 receptor agonists and preventing cardiovascular events.

Shared insight on the optimal management of patients who have macular edema following retinal vein occlusion.

Jennifer B. Green, MD, and Dennis Bruemmer, MD, PhD, have a conversation on the rise of Type 2 diabetes worldwide, and the available and upcoming treatment options.

A panel of experts discuss the best ways to treat peripheral arterial disease after revascularization.

Expert rheumatologists work together to elucidate the current treatment paradigm for patients with systemic lupus erythematous or idiopathic inflammatory myopathies.

Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, and Douglas DiRuggiero, DMSc, PA-C, discuss the management of atopic dermatitis with a focus on newer agents, including JAK inhibitors, currently in the drug approval pipeline.

Recommendations for properly treating pediatric and adult patients with inflammatory bowel disease based on common changes to the disease trajectory and it’s progressive nature.

James Januzzi, MD, and Javed Butler, MD, MPH, MBA, review recent updates in the recommendations for optimal medical care for patients with heart failure with reduced ejection fraction.